SE431985B - Analogiforfarande for framstellning av imidazo/1,2-a/kinoliner - Google Patents
Analogiforfarande for framstellning av imidazo/1,2-a/kinolinerInfo
- Publication number
- SE431985B SE431985B SE7800475A SE7800475A SE431985B SE 431985 B SE431985 B SE 431985B SE 7800475 A SE7800475 A SE 7800475A SE 7800475 A SE7800475 A SE 7800475A SE 431985 B SE431985 B SE 431985B
- Authority
- SE
- Sweden
- Prior art keywords
- formula
- absorption
- mixture
- ethyl
- imidazo
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 18
- 238000002360 preparation method Methods 0.000 title description 4
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 91
- 150000001875 compounds Chemical class 0.000 claims description 70
- 239000002253 acid Substances 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- -1 2-piperidino-ethyl group Chemical group 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 239000002585 base Substances 0.000 claims description 6
- 150000003863 ammonium salts Chemical class 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000002443 hydroxylamines Chemical class 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- HWQZCXHXDLUAQR-UHFFFAOYSA-N piperidine-2,3-diol Chemical compound OC1CCCNC1O HWQZCXHXDLUAQR-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 description 89
- 239000000203 mixture Substances 0.000 description 88
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- 239000000243 solution Substances 0.000 description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 59
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 52
- 238000002329 infrared spectrum Methods 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 35
- 239000000460 chlorine Substances 0.000 description 29
- 238000010992 reflux Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 239000013078 crystal Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 11
- LOAUVZALPPNFOQ-UHFFFAOYSA-M quinaldate Chemical compound C1=CC=CC2=NC(C(=O)[O-])=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-M 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 5
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- LNYZXZVWQOHRPE-UHFFFAOYSA-N 4-chloro-7-methoxyquinolin-2-amine Chemical compound ClC1=CC(N)=NC2=CC(OC)=CC=C21 LNYZXZVWQOHRPE-UHFFFAOYSA-N 0.000 description 2
- COPVGAZQEGEQRE-UHFFFAOYSA-N 7-chloro-4-propan-2-yloxyquinolin-2-amine Chemical compound ClC1=CC=C2C(OC(C)C)=CC(N)=NC2=C1 COPVGAZQEGEQRE-UHFFFAOYSA-N 0.000 description 2
- YABOAQWSZMINTJ-UHFFFAOYSA-N 8-chloro-5-propan-2-yloxyimidazo[1,2-a]quinoline-2-carboxylic acid Chemical compound ClC1=CC=C2C(OC(C)C)=CC3=NC(C(O)=O)=CN3C2=C1 YABOAQWSZMINTJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- IDSSTNLBDSSKGZ-UHFFFAOYSA-N ethyl 5,8-dimethoxyimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=C(OC)C=C2N3C=C(C(=O)OCC)N=C3C=C(OC)C2=C1 IDSSTNLBDSSKGZ-UHFFFAOYSA-N 0.000 description 2
- DXOLLHNULHSBKM-UHFFFAOYSA-N ethyl 8-chloroimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=C(Cl)C=C2N3C=C(C(=O)OCC)N=C3C=CC2=C1 DXOLLHNULHSBKM-UHFFFAOYSA-N 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- KZTWONRVIPPDKH-UHFFFAOYSA-N hydroxyethyl piperidine Natural products OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- HPSWWGPGSAZTLW-UHFFFAOYSA-N quinolin-2-yl hydrogen carbonate Chemical compound C1=CC=CC2=NC(OC(=O)O)=CC=C21 HPSWWGPGSAZTLW-UHFFFAOYSA-N 0.000 description 2
- DASZTFGYDXJWBT-UHFFFAOYSA-N quinoline-2-carboxylic acid;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(C(=O)O)=CC=C21 DASZTFGYDXJWBT-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WIZBUSFNRCWWMJ-UHFFFAOYSA-N 2-amino-7-chloro-1h-quinolin-4-one Chemical compound C1=CC(Cl)=CC2=NC(N)=CC(O)=C21 WIZBUSFNRCWWMJ-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- QDJRRGKJFMMTQC-UHFFFAOYSA-N 4,7-dichloroquinolin-2-amine Chemical compound C1=CC(Cl)=CC2=NC(N)=CC(Cl)=C21 QDJRRGKJFMMTQC-UHFFFAOYSA-N 0.000 description 1
- PZSIZHAXEONTPW-UHFFFAOYSA-N 4,7-dimethoxyquinolin-2-amine Chemical compound COC1=CC(N)=NC2=CC(OC)=CC=C21 PZSIZHAXEONTPW-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- WHFKEBBQPCDRND-UHFFFAOYSA-N 4-chloroquinolin-2-amine Chemical compound C1=CC=CC2=NC(N)=CC(Cl)=C21 WHFKEBBQPCDRND-UHFFFAOYSA-N 0.000 description 1
- LRMNFFRHIXAPMX-UHFFFAOYSA-N 4-methoxyquinolin-2-amine Chemical compound C1=CC=C2C(OC)=CC(N)=NC2=C1 LRMNFFRHIXAPMX-UHFFFAOYSA-N 0.000 description 1
- IHLOIMORUVNXBR-UHFFFAOYSA-N 4-propan-2-yloxyquinolin-2-amine Chemical compound C1=CC=C2C(OC(C)C)=CC(N)=NC2=C1 IHLOIMORUVNXBR-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- LFNYFPRSHXRDDH-UHFFFAOYSA-N 5-chloroquinolin-2-amine Chemical compound ClC1=CC=CC2=NC(N)=CC=C21 LFNYFPRSHXRDDH-UHFFFAOYSA-N 0.000 description 1
- YTLBWWFUMFNEDB-UHFFFAOYSA-N 5-methoxyimidazo[1,2-a]quinoline-2-carboxylic acid Chemical compound C1=CC=C2C(OC)=CC3=NC(C(O)=O)=CN3C2=C1 YTLBWWFUMFNEDB-UHFFFAOYSA-N 0.000 description 1
- OWXPWJUFPAYGPZ-UHFFFAOYSA-N 5-propan-2-yloxy-1H-imidazole Chemical compound C(C)(C)OC1=CN=CN1 OWXPWJUFPAYGPZ-UHFFFAOYSA-N 0.000 description 1
- QXGSBXTUXCTJII-UHFFFAOYSA-N 6-chloroquinolin-2-amine Chemical compound C1=C(Cl)C=CC2=NC(N)=CC=C21 QXGSBXTUXCTJII-UHFFFAOYSA-N 0.000 description 1
- HFDLDPJYCIEXJP-UHFFFAOYSA-N 6-methoxyquinoline Chemical compound N1=CC=CC2=CC(OC)=CC=C21 HFDLDPJYCIEXJP-UHFFFAOYSA-N 0.000 description 1
- MZELRJFWXXYUIM-UHFFFAOYSA-N 7-bromo-4-chloroquinolin-2-amine Chemical compound C1=CC(Br)=CC2=NC(N)=CC(Cl)=C21 MZELRJFWXXYUIM-UHFFFAOYSA-N 0.000 description 1
- CVUUCFIVYYDLHL-UHFFFAOYSA-N 7-chloroquinolin-2-amine Chemical compound C1=CC(Cl)=CC2=NC(N)=CC=C21 CVUUCFIVYYDLHL-UHFFFAOYSA-N 0.000 description 1
- UAVDJXVSYQNMSW-UHFFFAOYSA-N 7-methoxy-4-propan-2-yloxyquinolin-2-amine Chemical compound CC(C)OC1=CC(N)=NC2=CC(OC)=CC=C21 UAVDJXVSYQNMSW-UHFFFAOYSA-N 0.000 description 1
- GSWUMGAQTSRPQB-UHFFFAOYSA-N 7-methoxyquinolin-2-amine Chemical compound C1=CC(N)=NC2=CC(OC)=CC=C21 GSWUMGAQTSRPQB-UHFFFAOYSA-N 0.000 description 1
- JWTBCVUMWAOWGF-UHFFFAOYSA-N 8-bromo-5-chloroimidazo[1,2-a]quinoline-2-carboxylic acid Chemical compound C1=C(Br)C=C2N3C=C(C(=O)O)N=C3C=C(Cl)C2=C1 JWTBCVUMWAOWGF-UHFFFAOYSA-N 0.000 description 1
- UPCYSANWJZRSLF-UHFFFAOYSA-N 8-methoxy-5-propan-2-yloxyimidazo[1,2-a]quinoline-2-carboxylic acid Chemical compound CC(C)OC1=CC2=NC(C(O)=O)=CN2C2=CC(OC)=CC=C21 UPCYSANWJZRSLF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000005420 bog Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ASOXBXKHINMQAO-UHFFFAOYSA-N ethyl 4,5-dihydroimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=CC=C2N3C=C(C(=O)OCC)N=C3CCC2=C1 ASOXBXKHINMQAO-UHFFFAOYSA-N 0.000 description 1
- YIUPWXITIZRYGM-UHFFFAOYSA-N ethyl 5-chloro-8-methoxyimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=C(OC)C=C2N3C=C(C(=O)OCC)N=C3C=C(Cl)C2=C1 YIUPWXITIZRYGM-UHFFFAOYSA-N 0.000 description 1
- HOVOFWGWVZZHHB-UHFFFAOYSA-N ethyl 5-methoxyimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=CC=C2N3C=C(C(=O)OCC)N=C3C=C(OC)C2=C1 HOVOFWGWVZZHHB-UHFFFAOYSA-N 0.000 description 1
- OGHMMRCWAKPAKU-UHFFFAOYSA-N ethyl 6-chloroimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=CC=C2N3C=C(C(=O)OCC)N=C3C=CC2=C1Cl OGHMMRCWAKPAKU-UHFFFAOYSA-N 0.000 description 1
- SAGCRAOSIFYOGG-UHFFFAOYSA-N ethyl 7-chloroimidazo[1,2-a]quinoline-2-carboxylate Chemical compound ClC1=CC=C2N3C=C(C(=O)OCC)N=C3C=CC2=C1 SAGCRAOSIFYOGG-UHFFFAOYSA-N 0.000 description 1
- BXHUOBLLCLMKBQ-UHFFFAOYSA-N ethyl 7-methoxyimidazo[1,2-a]quinoline-2-carboxylate Chemical compound COC1=CC=C2N3C=C(C(=O)OCC)N=C3C=CC2=C1 BXHUOBLLCLMKBQ-UHFFFAOYSA-N 0.000 description 1
- HWHOHGXWZFLLPO-UHFFFAOYSA-N ethyl 8-bromo-5-chloroimidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=C(Br)C=C2N3C=C(C(=O)OCC)N=C3C=C(Cl)C2=C1 HWHOHGXWZFLLPO-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- WWWTVOIRLUISCN-UHFFFAOYSA-N ethyl imidazo[1,2-a]quinoline-2-carboxylate Chemical compound C1=CC=C2N3C=C(C(=O)OCC)N=C3C=CC2=C1 WWWTVOIRLUISCN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- VUEWYMPSGWCXLN-UHFFFAOYSA-N imidazo[1,2-a]quinoline-2-carboxylic acid Chemical compound C1=CC=C2N3C=C(C(=O)O)N=C3C=CC2=C1 VUEWYMPSGWCXLN-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2377/77A GB1596652A (en) | 1977-01-20 | 1977-01-20 | Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7800475L SE7800475L (sv) | 1978-07-21 |
| SE431985B true SE431985B (sv) | 1984-03-12 |
Family
ID=9738484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7800475A SE431985B (sv) | 1977-01-20 | 1978-01-16 | Analogiforfarande for framstellning av imidazo/1,2-a/kinoliner |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4279912A (en]) |
| JP (1) | JPS5390297A (en]) |
| AT (1) | AT363475B (en]) |
| AU (1) | AU512434B2 (en]) |
| BE (1) | BE863082A (en]) |
| CA (1) | CA1097647A (en]) |
| CH (1) | CH630085A5 (en]) |
| DE (1) | DE2802493A1 (en]) |
| DK (1) | DK150071C (en]) |
| ES (1) | ES466143A1 (en]) |
| FR (1) | FR2378031A1 (en]) |
| GB (1) | GB1596652A (en]) |
| IE (1) | IE46646B1 (en]) |
| IL (1) | IL53757A (en]) |
| LU (1) | LU78902A1 (en]) |
| NL (1) | NL7800744A (en]) |
| PT (1) | PT67550B (en]) |
| SE (1) | SE431985B (en]) |
| ZA (1) | ZA7897B (en]) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE441449B (sv) * | 1979-02-09 | 1985-10-07 | Roussel Uclaf | Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat |
| GR76063B (en]) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
| IL66835A (en) * | 1981-09-24 | 1988-05-31 | Roussel Uclaf | 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them |
| US4472401A (en) * | 1981-11-27 | 1984-09-18 | Roussel Uclaf | Pyrimido-quinoxalines having antiallergic properties |
| US4510143A (en) * | 1982-02-17 | 1985-04-09 | Roussel Uclaf | Antiallergic pyrimido[1,2-a]quinoxalin-2-carboxylic acid derivatives |
| ZA836701B (en) * | 1982-10-01 | 1984-10-31 | Roussel Uclaf | Imidazo(1,2-a)quinolines |
| US4992428A (en) * | 1988-05-05 | 1991-02-12 | Sandoz Pharm. Corp. | 5-aryl-substituted-2,3-dihydro-imidazo[1,2-a]furo- and thieno pyridines |
| US5141932A (en) * | 1988-05-05 | 1992-08-25 | Sandoz Pharmaceuticals Corp. | 5-Aryl-substituted-2,3-dihydro-imidazo(1,2-a)furo- and thieno pyridines |
| AU5533996A (en) * | 1996-04-04 | 1997-10-29 | University Of Nebraska Board Of Regents | Synthetic triple helix-forming compounds |
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| US9226373B2 (en) | 2013-10-30 | 2015-12-29 | John Joseph King | Programmable light timer and a method of implementing a programmable light timer |
| CN108794485B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类toll样受体调节剂、其药物组合物、制备方法与用途 |
| US11339138B2 (en) * | 2018-10-05 | 2022-05-24 | E. I. Du Pont De Nemours And Company | Process and intermediates for the preparation of certain nematicidal sulfonamides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624093A (en) * | 1970-03-10 | 1971-11-30 | American Home Prod | 5,6-disubstituted-2,3,5,6-tetrahydroimidazo-{8 2,1-{60 {9 isoquinolin-6-ols |
| GB1347493A (en) * | 1971-02-11 | 1974-02-27 | Aspro Nicholas Ltd | Benzazine derivatives |
| GB1488412A (en) * | 1975-01-16 | 1977-10-12 | Wyeth John & Brother Ltd | Imidazo(1,2-a)quinolines |
| US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
-
1977
- 1977-01-20 GB GB2377/77A patent/GB1596652A/en not_active Expired
-
1978
- 1978-01-04 FR FR7800141A patent/FR2378031A1/fr active Granted
- 1978-01-05 IL IL53757A patent/IL53757A/xx unknown
- 1978-01-06 ZA ZA00780097A patent/ZA7897B/xx unknown
- 1978-01-16 US US05/869,842 patent/US4279912A/en not_active Expired - Lifetime
- 1978-01-16 SE SE7800475A patent/SE431985B/sv not_active IP Right Cessation
- 1978-01-19 ES ES466143A patent/ES466143A1/es not_active Expired
- 1978-01-19 LU LU78902A patent/LU78902A1/xx unknown
- 1978-01-19 CA CA295,312A patent/CA1097647A/fr not_active Expired
- 1978-01-19 BE BE184453A patent/BE863082A/xx not_active IP Right Cessation
- 1978-01-19 PT PT67550A patent/PT67550B/pt unknown
- 1978-01-19 IE IE119/78A patent/IE46646B1/en unknown
- 1978-01-19 DK DK027078A patent/DK150071C/da not_active IP Right Cessation
- 1978-01-19 AU AU32553/78A patent/AU512434B2/en not_active Expired
- 1978-01-20 NL NL7800744A patent/NL7800744A/xx not_active Application Discontinuation
- 1978-01-20 AT AT0043078A patent/AT363475B/de active
- 1978-01-20 CH CH65878A patent/CH630085A5/fr not_active IP Right Cessation
- 1978-01-20 JP JP444378A patent/JPS5390297A/ja active Granted
- 1978-01-20 DE DE19782802493 patent/DE2802493A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62147B2 (en]) | 1987-01-06 |
| BE863082A (fr) | 1978-07-19 |
| AU512434B2 (en) | 1980-10-09 |
| PT67550B (fr) | 1980-01-14 |
| PT67550A (fr) | 1978-02-01 |
| DK27078A (da) | 1978-07-21 |
| SE7800475L (sv) | 1978-07-21 |
| DE2802493A1 (de) | 1978-07-27 |
| DK150071C (da) | 1987-06-15 |
| US4279912A (en) | 1981-07-21 |
| AU3255378A (en) | 1979-07-26 |
| AT363475B (de) | 1981-08-10 |
| GB1596652A (en) | 1981-08-26 |
| FR2378031B1 (en]) | 1981-01-16 |
| ATA43078A (de) | 1981-01-15 |
| JPS5390297A (en) | 1978-08-08 |
| IE46646B1 (en) | 1983-08-10 |
| IL53757A0 (en) | 1978-04-30 |
| FR2378031A1 (fr) | 1978-08-18 |
| IE780119L (en) | 1978-07-20 |
| LU78902A1 (fr) | 1978-09-18 |
| CA1097647A (fr) | 1981-03-17 |
| ES466143A1 (es) | 1979-06-01 |
| DE2802493C2 (en]) | 1989-01-26 |
| CH630085A5 (fr) | 1982-05-28 |
| ZA7897B (en) | 1979-02-28 |
| NL7800744A (nl) | 1978-07-24 |
| IL53757A (en) | 1982-02-28 |
| DK150071B (da) | 1986-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4738971A (en) | N-aryl-1,2-dihydro-4-substituted-1-alkyl-2-oxo-quinoline-3-carboxamides | |
| CA2494700C (en) | Calcium receptor modulating compound and use thereof | |
| RU2168511C2 (ru) | Производные пиридазинохинолина | |
| SE431985B (sv) | Analogiforfarande for framstellning av imidazo/1,2-a/kinoliner | |
| BG60337B2 (bg) | 4-амино-2-(4-)1,4-бензодиоксан-2-карбонил(пиперазин-1-ил или хомопиперазин-1-ил)хиназолини с антихипертензивно действие | |
| KR880002353B1 (ko) | 퀴놀린 화합물 및 그의 제조방법 | |
| EP0002482A1 (de) | 4-Hydroxy-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| HK62191A (en) | A 6-fluoro-1,4-dihydro-4-oxo-7-substituted piperazinyl-quinoline-3-carboxylic acid derivative and the method for preparing the same | |
| US4299831A (en) | 2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them | |
| JPS6038357A (ja) | チオエーテル、その製造法及びこの化合物を含有しアレルギー性疾患を撲滅する薬剤 | |
| US3478040A (en) | Glyceryl 2-(x,y,z-substituted anilino) nicotinates | |
| JPH0141637B2 (en]) | ||
| US4232024A (en) | 1-Oxo-1H-pyrimido[6,1-b]benzthiazole derivatives | |
| JPS6231718B2 (en]) | ||
| US4632923A (en) | Substituted hetero spiro pyridine derivatives as anti-allergy and anti-inflammatory agents | |
| US4163785A (en) | Benzothiazepine compounds and compositions | |
| JPH0559914B2 (en]) | ||
| JPH10505333A (ja) | イミダゾピリジン−アゾリジノン | |
| JPS60184086A (ja) | 化合物 | |
| JPS6045199B2 (ja) | 新規なイミダゾベンゾオキサジン及びそれらを含む製薬組成物 | |
| JPS6089480A (ja) | ピリドンカルボン酸誘導体 | |
| US4210758A (en) | 1,5-Dihydro-1,5-dioxo-N-1H-tetrazol-5-yl-4H-[1]benzopyrano[3,4-b]pyridine-2-carboxamides | |
| JPH066586B2 (ja) | 置換スピロピリジン誘導体、それらを含む医薬組成物、ならびにそれらの化合物および組成物の製造方法 | |
| NO152172B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater | |
| US3567716A (en) | 1,8-naphthyridine derivatives and intermediates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7800475-1 Effective date: 19901211 Format of ref document f/p: F |